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Introduction
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INTRODUCTION 
        The introduction of general anesthetics into clinical practice date 
back to 150 years. It stands as one of the pioneering innovations of 
medicine, that lead to the development of modern surgery and spawned 
the speciality of anaesthesiology. General anaesthesia can broadly be 
defined as a drug-induced reversible depression of the central nervous 
system resulting in the loss of perception to all external stimuli. It is 
usually defined as a triad of amnesia, analgesia, and muscle relaxation. 
         Since introduction of general anaesthesia, no ideal induction agent 
has been discovered which provides stable hemodynamic conditions 
during endotracheal intubation. 
        Airway management and patient safety is the most important 
aspect of patient management in general anaesthesia. Safest and gold 
standard method of protecting airway, delivering anaesthetic gases and 
protection against aspiration is securing airway with endotracheal  
tube
 (1, 2).
 
        An ideal induction agent should have hemodynamic stability and 
minimal intubation stress response, rapid clearance. The laryngoscopy 
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and intubation causes stress response leading to changes in hemodynamic 
parameters which can be detrimental to patients who are at cardiac risk
(3). 
These hemodynamic responses can affect myocardial perfusion in a 
negative way by increasing the myocardial oxygen demand and cardiac 
work load which can lead to ischemia. 
        During intubation, stimulation of laryngeal and tracheal tissues 
causes catecholamine discharge which can cause an increase in 
sympathetico adrenergic activity causing an increase in heart rate and 
systemic arterial pressure. Uses of general anaesthetic agent with 
intravenous induction can often cause hypotension by many mechanisms. 
Most important are suppressive effects of these agents on myocardial 
contractility, baroreceptor activity, sympathetic activity and central 
nervous activity. 
        Propofol is most commonly used agent for induction in general 
anaesthesia. It is a short acting IV anesthetic agent but it causes 
hemodynamic instability by causing profound hypotension. It also causes 
pain on injection. Allergic reactions are also being documented. 
        Etomidate is recently added drug to induction agent and being used 
in common practice in recent days due to its cardio stable nature. 
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        It also has side effects like nausea, vomiting, increase in 
epileptogenic activity in patient with seizures, myoclonic activity. Rare 
but most important side effect of etomidate is decrease in serum cortisol 
by inhibition of 11 – beta–hydroxylase enzymes(26) even after single dose 
for up to 24 hours but this decrease was found to be within physiological 
range.  
        The primary objective of this study was to compare the efficacy of 
two different induction agents (Inj. Propofol and Inj. Etomidate) in 
maintaining hemodynamic stability during induction and following 
endotracheal intubation in elective surgery. 
 
 
 
 
  
Aims
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AIMS AND OBJECTIVES 
AIM OF STUDY 
       To compare the effect of intravenous induction agents propofol and 
etomidate in maintaining hemodynamic stability during and after 
endotracheal intubation. 
OBJECTIVES 
1)  To assess the effect of the induction agent on the variation in heart 
rate during laryngoscopy and intubation. 
2)  To assess the variation of blood pressure during laryngoscopy and 
intubation. 
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REVIEW OF LITERATURE 
        Ye L et al
(4) 
[2017]
 
, did a study of Comparison between Etomidate 
and Propofol Anaesthesia in Patients Undergoing Gastrointestinal 
Endoscopy: A Systematic Review and Meta-Analysis. 1115 patients were 
included in this meta-analysis based on six randomized controlled trials. 
There were no significant differences identified regarding duration of 
anaesthesia between etomidate and propofol group. Mean arterial 
pressure, recovery time, heart pulse, SPO2 at intubation, patient 
satisfaction, hypotension, changes of heart rate and nausea-vomiting were 
also comparable in both the groups. In Comparison with propofol, 
etomidate showed reduced apnea or hypoxemia and injection pain but 
with an increased myoclonus.        
Baradari AG et al
(5) 
[2017] did a randomized clinical trial 
comparing hemodynamic response to ketamine-propofol combination 
versus etomidate during anaesthesia induction in patients with left 
ventricular dysfunction undergoing coronary artery bypass graft surgery. 
In his study a total of 84 patients with ischemic left ventricular 
dysfunction (EF<40%) where randomly divided into 2 groups. Patients in 
group A received etomidate 0.2 mg/kg and placebo, whereas group B 
received   ketamine 1mg/kg and propofol 1.5 mg/kg. Hemodynamic 
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variables systolic blood pressure, diastolic blood pressure, mean arterial 
pressure and heart rate were measured during and after laryngoscopy and 
before intubation at post intubation at 1, 2 and 3mins. The decrease in all 
hemodynamic parameters were greater in ketofol group (group B) than in 
etomidate group (group A) (p<0.005).They found that etomidate provides 
more hemodynamic stability when compared to ketofol in patients 
undergoing CABG surgery 
       Meena K, et al
(6)
[2016] did a comparative study of effects of 
propofol, etomidate and propofol plus etomidate induction on 
hemodynamic response to endotracheal intubation: A randomized 
controlled trial. 90 patients in the age group of 15-60 years of either sex 
and ASA physical status I and II who were scheduled for elective 
surgery. Group 1- inj. propofol (2.5mg/kg), Group 2-inj.etomidate 
(0.3mg/kg), Group 3 - inj. propofol (1mg/kg) plus etomidate (0.2mg/kg). 
Systolic blood pressure, diastolic blood pressure, mean arterial pressure 
and heart rate were measured at variable intervals following intubation. In 
this study they founded that etomidate plus propofol has better 
hemodynamic stability than etomidate alone at 1 min , though etomidate 
was equally stable at other points. 
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         Aggarwal et al
(7)
 [2016] did a comparative study between propofol 
and etomidate under general anaesthesia. He studied 100 ASA I and II 
patients in the age group of 18 to 60 who were scheduled for elective 
procedure under general anaesthesia. 100 patients were divided randomly 
in 2 groups receiving propofol (2mg/kg) and etomidate (0.3mg/kg) as 
induction agents. In the study he found out that etomidate group had little 
changes in mean arterial pressure (MAP) and heart rate when compared 
to propofol from baseline value. Propofol group had pain on injection 
during administration and incident of myoclonus were high in etomidate. 
They concluded that etomidate is better agent for induction than propofol 
in the view of hemodynamic stability. 
             Wu J, et al
8) 
[2013], did a comparison study of anesthetic 
regimens using etomidate and propofol in patients undergoing first-
trimester abortion. A Double-blind, Randomized clinical trial. In this 
study they compared recovery time, side effects, safety of 6 distinct 
anesthetic regime for first trimester abortion. 240 women scheduled for 
surgical abortion from 6 to 8 weeks of gestation were randomized into six 
groups - (n=40) of propofol: group P (2 mg/kg propofol alone), group PF 
(2 mg/kg propofol+1 mcg/kg fentanyl), group PMF (2 mg/kg propofol+ 
1 mcg/kg fentanyl+0.02 mg/kg midazolam) and (n=40) of etomidate: 
group E (0.2 mg/kg etomidate alone)group EF (0.2 mg/kg etomidate+ 
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1 mcg/kg fentanyl)group EMF (0.2 mg/kg etomidate+1 mcg/kg 
fentanyl+0.02 mg/kg midazolam).Vital signs such as pulse oxygen 
saturation (SpO2), mean arterial pressure (MAP) and heart rate were 
recorded. The recovery time and side effects were also recorded. They 
showed that etomidate is much safer in terms of hemodynamics in patient 
undergoing first trimester abortion. Usage of lower dose of etomidate 
with fentanyl and midazolam were more beneficial than the use of 
etomidate with or without fentanyl in avoiding myoclonus and post-
operative nausea and vomiting. 
         Shah Sb
 (9)
 [2015] did a study in Comparison of hemodynamic 
effects of intravenous etomidate versus propofol during induction and 
intubation using entropy guided hypnosis levels. 60 ASA I & II patients 
in the age group 20-60 years where scheduled for modified radical 
mastectomy and they were randomly allocated in two groups based on 
induction agent Etomidate and Propofol. Both groups were premedicated 
with intravenous midazolam 0.03 mg /kg   and fentanyl 2 μg/kg. After 
induction with the desired agent titrated to entropy 40, vecuronium  
0.1 mg /kg   was used to administer neuromuscular blockade. Heart rate, 
systolic, diastolic and mean arterial pressures, response entropy and state 
entropy were recorded at baseline, induction and upto three minute post 
intubation. The study concluded that etomidate provided more 
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hemodynamic stability without the requirements of any rescue drug in 
96.6% patient whereas ephedrine was in 36% patient under propofol 
group 
        Sanjeeta Umbarkar et al
(10)
 [2015] studied the effects of single 
induction dose of etomidate on stress response in adult patients 
undergoing cardiac vascular surgeries with cardiopulmonary bypass .60 
patients were randomly allotted in etomidate and fentanyl -midazolam 
group, 30 in each group. Blood samples for plasma cortisol and blood 
sugar levels were collected before induction of anaesthesia, after aortic 
cross clamping on cardio pulmonary bypass and 24 hrs postoperatively. 
In the study they found that even though etomidate causes adrenocortical 
suppression it was beneficial in reducing stress response by decreasing 
cortisol levels and blood sugar levels during intraoperative and 
postoperative periods. It was also seen that hemodynamic is well 
maintained in etomidate group compared to high dose opioids, the 
cortisol and blood sugar levels returns to normal following 24hrs post-
surgery, thus single dose of etomidate does not cause much harm by 
adrenocortical suppression. 
        Song JC, et al
(11)
 [2015] did a study on etomidate anaesthesia 
during ERCP caused more stable haemodynamic responses compared 
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with Propofol: A Randomized Clinical Trial. In his study 80 patients 
undergoing ERCP were randomly assigned under etomidate or propofol 
group. Cardiovascular parameters and procedure related time were 
recorded during ERCP. They found that mean arterial pressure (MAP) 
values in the etomidate group showed less variation than those in 
propofol group (P<0.05). The recovery time and duration of ERCP was 
similar in both groups thus they concluded that etomidate anaesthesia 
during ERCP was hemodynamically stable when compared with 
propofol. 
        Kahlon A et al
(12)
[2014], did a randomized double blinded placebo 
control study on 75 patients. They were divided into 3 groups, 25 patients 
in each group. Group I received placebo- 1 ml of normal saline, Group II 
received 1 ml of 2% lignocaine and Grorp III received 1 ml of midazolam 
(1mg) as premedication 2 mins before induction with etomidate 
0.3mg/kg. they observed that incidence of myoclonus in placebo group 
was 76%, lignocaine group 44% and midazolam group was 28%. 
Masoudifar N, et al
(13)
[2013] did a comparison of cardiovascular 
response to laryngoscopy and tracheal intubation after induction of 
anaesthesia by propofol and etomidate. In his study 25 consenting ASA  
I and II patients were randomly divided into two groups, etomidate 
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(0.3mg/kg) in group A and propofol (2-2.5 mg/kg) in group B and 
evaluated their cardiovascular responses including systolic blood 
pressure, diastolic blood pressure, mean arterial pressure and heart rate 
and SPO2.The above parameters were measured before, during and after 
laryngoscopy and at 1,3,5,10 min after the intubation. The changes of 
systolic blood pressure (P=0,019), mean arterial pressure  (P=0.008) in 
the group B was significantly higher than  the group A. No significant 
difference between the groups A  and B in terms of  heart rate  and SPO2. 
Thus concluding that etomidate is more stable hemodynamically than 
propofol. 
Moller et al
(14) 
[2013]
  
used propofol and etomidate induction of 
general anaesthesia accompanied by BIS monitoring. 48 patients were 
studied, the mean arterial pressure , Cardiac index(CI) and systemic 
vascular resistance index(SVRI) were  recorded.  The haemodynamic 
variables were higher in etomidate group upto 7mins after intubation. 
There was significant hypotension in propofol group. Heart rate and mean 
arterial pressure was maintained in etomidate group. Incidence of 
hypertension and tachycardia was more in etomidate group. Hence 
etomidate was found to be stable compared to  propofol in hemodynamic 
parameters 
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  Tokul S, et al
(15) 
[2009] did a study of comparison of etomidate- 
remifentanil and propofol -remifentanil sedation in patients scheduled for 
colonoscopy. In his study 60 patients under the age group of 18 to 65 
years where scheduled for elective colonoscopy under sedation. 
Remifentanil was given in the continuous infusion at the rate of  
(0.1 mcg/kg/min). After 2 mins propofol (initial dose of 0.5 mg/kg 
maintained with 0.25 mg/kg) or etomidate (initial dose of 0.1 kg 
maintained with 0.05 mg/kg were given). Heart rate, mean arterial 
pressure, SPO2 and Ramsay sedation score where recorded at baseline, 
every 2 mins for the first 10 mins and every 5 mins thereafter till the 
completion of procedure. They found that apnea and hypotension were 
significantly lower in the etomidate group (P<0.001). Thus he concluded 
that etomidate-Remifentanil combination provided more hemodynamic 
stability than propofol – remifentanil. 
       Hildreth AN, et al
(16)
[2008] performed a prospective randomized 
controlled study. Adrenal suppression following single dose of etomidate 
for rapid sequence induction. In his study Adult trauma patients were 
admitted at level I trauma centre who required a rapid sequence induction 
where randomized to receive etomidate 0.3 mg/kg, succinylcholine 
1mg/kg (E group ) or fentanyl 100 mcg, midazolam 5mg and 
succinylcholine 1mg/kg (FM group). Baseline values of serum cortisol 
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level where measured before rapid sequence induction. A post intubation 
serum cortisol level where measured at 4 to 6 hours after intubation. An 
ACTH stimulation test was performed. The use of etomidate for rapid 
sequence induction in trauma patients, showed the evidence of 
adrenocortical insufficiency and it had caused increased hospital and ICU 
stay. Further studies were needed for evaluating the safety of this drug in 
trauma patients. 
Schmidt et al
(17) 
[1999] found in their study that hypotension 
caused by propofol is due to the reduction of heart’s preload and 
afterload. This hypotension sue to propofol are not synchronized with 
heart’s compensatory responses such as increased cardiac output and 
increased heart rate. These changes in hemodynamic drop would be 
intensified by high doses of the drug and high speed injection of the drug. 
In our study we got similar results in group I which is after induction with 
propofol there was hypotension which is not synchronized with increased 
heart rate. 
        Harris et al
(18)
[1988] did a study comparing the hemodynamic 
response to tracheal intubation in 303 patients in whom anaesthesia was 
induced with either thiopentone 4 mg/kg, etomidate 0.3 mg/kg or 
propofol 2.5 mg/kg with or without fentanyl 2 μg/kg. In patients who 
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were induced only with propofol had significant decrease in arterial blood 
pressure the values of which did not increase above baseline value after 
intubation. There was significant increase in arterial pressure following 
intubation with thiopentone or etomidate alone. Increase in heart rate 
occurred with all agents after laryngoscopy and intubation. When 
fentanyl was added to propofol it resulted in lower arterial pressure on 
comparing with induction agent alone. We got similar results in our 
study. Significant decrease in arterial blood pressure occurred with 
propofol, while with etomidate there was significant increase in arterial 
pressure following intubation. Also increase in heart rate occurred with 
all agents after laryngoscopy and intubation. 
        
  
History
of
Intravenous
Anaesthetics
15 
HISTORY OF INTRAVENOUS ANAESTHETIC DRUGS 
        William Harvey described the complete and continuous 
intravascular circuit in 1628. Wren
(19) 
introduced intravenous anaesthesia 
in 1656  a technique using a goose quill and a bladder to inject  wine and 
ale into a dog’s vein.  The invention of the hollow needle in 1843 and 
hypodermic syringe in 1853 allowed IV administration of drugs. In 
1900s, diverse drugs including ether had been given for sedation. In 1855, 
Wood published a paper on the injection of opiates into painful spot by 
use of hollow needle and a glass syringe. 
In 1872, Pierre Ore of Lyons performed first successful surgical 
anaesthesia by injecting chloral hydrate. In 1909, Ludwig Burkhardt 
produced surgical anaesthesia by intravenous injection of chloroform and 
ether in Germany. 
           First barbiturate was synthesized in 1903 by Fisher and Von 
Mering.   Weese and Scharpff synthesized the short-acting hexobarbital 
in 1932 but the introduction of thiopental by Lundy and Tovell in 1934 
provided greater advancement dominating induction of anaesthesia for 
the next half century.  
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        Price in 1960 suggested that thiopental redistributes from brain to 
muscle rather than to fat. This explained rapid awakening following 
thiopental induction. This work led to discovery of many 
pharmacokinetic and pharmacodynamics concepts.  
        Thiopental decreased cerebral metabolism and cerebral blood flow, 
leading to its use in the 1970s to protect the brain from hypoxic insult. 
Methohexital, a shorter-acting barbiturate with central nervous system-
stimulating properties was introduced in 1956 and it still remains a 
popular anesthetic for electroconvulsive therapy (ECT). 
        In 1962, Ketamine was synthesized by Dr. Calvin Stevens. 
Etomidate was first described by Paul Janssen and his colleagues in 1964. 
Propofol was first synthesized in 1977 by imperial chemical industries. 
Cremophor EL, the solvent which was formulated produced severe 
allergic reactions and was withdrawn from usage. Then propofol was 
formulated with egg lecithin, soya bean oil, glycerol, it entered practice 
and grained more importance. 
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STRESS RESPONSE AND ANAESTHESIA 
        The body reacts to external stimuli, minor to major both locally and 
generally leading to widespread endocrinal, metabolic, and biochemical 
reactions throughout the whole body. So amplitude of the response 
depends upon severity, intensity and duration of stimulus. The complex 
interplay of substances following the trigger between the hypo thalamo 
pituitary axis and classical neuro endocrine hormone system and 
autonomic nervous system results in a reaction called stress response or 
alarm reaction. 
The stress response leads to secretion of various anabolic and 
catabolic hormones resulting in hypermetabolic state. In acute phase this 
helps in maintaining hemodynamic state. If it is prolonged, the 
continuous hypermetabolic state results in exhaustion of essential 
components of the body leading to decreased resistance, increased 
mortality and morbidity. The net effect of stress response “The 
Neuroendocrine outflow”:  
 Cardiovascular changes: - Rise in cardiac output, heart rate, 
blood pressure, increased myocardial contractility, increase 
oxygen demand.  
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 Blood volume distribution: – Peripheral and splanchnic 
vasoconstriction coronary and cerebral vasodilatation.   
 Respiratory Changes- Increased respiratory rate.  
 Fluid and electrolyte changes: - Sodium and water retention.  
 Coagulation: - Hyper coagulability and fibrinolysis. 
 Immunosuppression: - Wound Infections.  
 Metabolic Changes: – Substrate mobilization hyperglycemia.  
 Urinary changes: – reduced urinary output. 
The stress changes are well tolerated in ASA grade I and II 
patients. In patients with co-morbidities these changes leads to life 
threatening complications. 
The primary stimuli of neuro-endocrine reflexes 
1. Hypotension 
2. Oxygen, carbon dioxide and hydrogen ion imbalance 
3. Anxiety and emotional disturbances 
4. Temperature variations 
5. Anaesthesia 
 Anesthetic drugs 
 Laryngoscopy and intubation 
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Following the mechanical stimulation of upper airway tract, 
efferents that are carried by glossopharyngeal nerve and via vagus nerve 
from tacheo-broncheal tree enhances the activity of cervical sympathetic 
afferent fibres resulting in transient increase in heart rate and blood 
pressure. 
 Light plane of anaesthesia 
 Pain 
6. Surgery 
The stress response is divided into two phases: 
 Acute or shock phase. 
 Slow phase. 
The stress hormones are 
 Autocrines: Catecholamines, Glucagon, Insulin. 
 Endocrines: Cortisol, Growth hormone, Vasopressin, Aldosterone, 
Renin-Angiotensin. 
 Paracrines: Cytokines, Leukotrienes etc. 
  
Physiological changes
during laryngoscopy
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PHYSIOLOGICAL CHANGES DURING 
LARYNGOSCOPY 
 
        The airway manipulations like laryngoscopy and endotracheal 
intubation are noxious stimuli. These external stimuli may produce 
profound changes in cardiovascular physiology primarily through reflex 
responses. Even though these responses are of short duration and causes 
minor consequence in healthy individuals, serious complications occur in 
those patients with underlying coronary artery disease, reactive airways 
or intracranial neuropathology. 
 
Cardiovascular Responses during Airway Manipulation 
  
21 
Cardiovascular Reflexes 
The cardiovascular response
(20)
to external and noxious airway 
manipulation are initiated by proprioceptors responding to tissue irritation 
in the supraglottic region and in the trachea. These receptors are located 
in close proximity to the airway mucosa, it consists of mechanoreceptors 
with small-diameter myelinated fibers. These fibers are slowly-adapting 
stretch receptors, with large-diameter myelinated fibers and polymodal 
endings of nonmyelinated nerve fibers. Autonomic activation is caused 
by glossopharyngeal and vagal afferent nerves that transmit these 
impulses to the brainstem there by activating sympathetic and 
parasympathetic nervous systems. 
Hypertension and tachycardia mediated by the cardio accelerator 
nerves and sympathetic chain ganglia are the most common response to 
airway manipulation in adults and adolescents. This response causes 
widespread release of norepinephrine from adrenergic nerve terminals. 
There is secretion of epinephrine from the adrenal medulla. Renin-
angiotensin system is also activated by the hypertensive responses to 
endotracheal intubation leading to release of renin from the renal 
juxtaglomerular apparatus which is innervated by β-adrenergic nerve 
terminals. 
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           Laryngoscopy and endotracheal intubation result in stimulation of 
the central nervous system seen by increases in electroencephalographic 
activity, cerebral metabolic rate, and cerebral blood flow. 
        Acute bronchospasm or a main stem bronchial intubation in a 
disturbed perfusion to poorly ventilated lung units causing desaturation of 
pulmonary venous blood. This events results in reduction in systemic 
arterial oxygen tension. In addition, institution of positive end expiratory 
pressure after endotracheal intubation causes a reduction in cardiac output 
mediated by decreased venous return to the left side of the heart from the 
pulmonary circulation. The impact of these changes can be profound in 
patients with severely compromised myocardial function and in patients 
with intravascular volume depletion. 
Intubation in the Presence of Cardiovascular Disease 
Myocardial ischemia occur when there is an imbalance between 
myocardial O2 supply and demand. Heart rate and myocardial wall 
tension are the two components that determine the myocardial oxygen 
demand.. Of the two increases in heart rate are of greatest concern 
because cardiac inotropism subserves cardiac chronotropism rate. Not 
only tachycardia increases myocardial O2 consumption per minute at 
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constant wall tension. But this changes in tachycardia causes decrease in 
diastolic period. 
        Patients with aneurysmal disease of the cerebral and aortic 
circulation are at risk of complications related to a sudden increase in BP 
during airway instrumentation. Laplace’s law defines the transmural wall 
tension of a blood vessel as the product of the pressure inside the vessel 
and its radius divided by the wall thickness. 
Implications for Patients with Neurovascular Disease 
In patients with intracranial aneurysms and arteriovenous 
malformations, periods of elevated arterial blood pressure causes these 
lesions  to rupture resulting in sudden and permanent neurologic injury. 
Therefore, neurosurgical anesthesiologists must pay careful attention to 
reducing these responses during the course of anesthetic induction and 
endotracheal intubation. 
Intubation in Patients with Neuropathological Disorders 
The cerebral blood flow (CBF) remain constant over the BP range 
of 50 to 150 mm Hg. This range is impaired when there is impaired 
cerebral autoregulation. When endotracheal intubation causes an increase 
in arterial blood pressure there is a marked increase in CBF and cerebral 
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blood volume which leads to increases in intra cranial pressure that can 
be dangerous. 
Prevention of Cardiovascular Responses 
 Technical Consideration: Minimizing Stimulation of Airway. 
Cardiovascular responses to airway manipulations can be reduced by 
limiting airway proprioceptor stimulation starting from the manipulation 
of the larynx itself. 
 
Laryngoscopy
 (21)
 itself is a moderately stimulating procedure. Use 
of a straight blade for elevation of the vaguely innervated posterior aspect 
of the epiglottis results in significant raise in arterial blood pressure than 
use of McCoy blade or other newer blades. The above chart shows the 
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effect of various laryngoscopes in hemodynamic changes to 
laryngoscopy. 
The act of passing an endotracheal tube is far more 
hemodynamically stimulating than just laryngoscopy. Insertion of a 
conventional laryngeal mask airway after induction of general anaesthesia 
with thiopental or propofol and fentanyl, cause less cardiovascular and 
endocrine response than laryngoscopy or endotracheal intubation. Topical 
anaesthesia
(22)
  when applied to the upper airway is effective in blunting 
hemodynamic responses to endotracheal intubation.  
        In contrast to topical anaesthesia of the airway, which provide 
inconsistent benefits, regional nerve blocks that involves the sensory 
pathways from the airway prevent hemodynamic responses to intubation. 
The superior laryngeal nerve innervates the superior surface of the larynx 
and the glossopharyngeal nerve innervates the oropharynx. Depositing 
local anesthetic on each cornua of the hyoid bone can block the superior 
laryngeal nerve (SLN). 
          The glossopharyngeal nerve blocked at the tonsillar pillars 
potentiates this effect by decreasing the stimulus of laryngoscopy. 
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The above chart shows the effect of lidocaine in attenuation of 
hemodynamic response to laryngoscopy. 
Intravenous Agents 
The anesthetic dose of intravenous anesthetic required for 
effectively blocking hemodynamic and intra cranial response responses to 
endotracheal intubation has remained an elusive goal. 
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        Propofol, barbiturates, and benzodiazepines are all associated with 
profound fall in blood pressure at doses that suppress the hemodynamic 
and intra cranial pressure (ICP) responses to intubation. The effective 
dose of etomidate for blocking this cardiovascular response to intubation 
can be identified by a burst-suppression pattern on EEG, which shows 
fairly deep cerebral depression. It is probably the only agent that by itself 
can achieve suppression of cardiovascular responses at a dose that does 
not cause undue arterial hypotension and compromise of coronary and 
cerebral perfusion. 
         It is clinically impractical to achieve sufficient anesthetic depth for 
preventing a hemodynamic response to intubation solely with an 
intravenous or inhalational agent a wide variety of anaesthetic drug 
combinations, adjuvants, or both have been used to potentiate anesthetic 
effects while minimizing hemodynamic depression. 
        Opioids are the adjuvants most commonly added to iv or inhaled 
agents to facilitate induction of anaesthesia and subsequent airway 
manipulation. Fentanyl is 100 times more potent than morphine. Fentanyl 
is not a short-acting agent, and the risk of prolonged postoperative 
respiratory depression following fentanyl must be kept in mind against 
the advantages of perioperative cardiovascular stability. With this risk in 
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mind, it is seen that pre-treatment with 2 µg/kg IV fentanyl, when given 
10 minutes before intubation during an infusion of propofol sufficient to 
reduce the Bispectral Index Score to 45, thus preventing a significant 
increase in heartrate and blood pressure  compared with awake pre  
anaesthetic values. Opioids with shorter onset and offset times have much 
added advantages over fentanyl for modulating circulatory responses to 
intubation. IV lidocaine may also blunt hemodynamic and 
cerebrovascular responses to intubation. When given in a bolus of 1.5 
mg/kg IV, it adds 0.3 MAC of anaesthetic potency. 
Inhalational Anesthetics 
 For inhalational anesthetics, endotracheal intubation in the dose 
range of the minimum alveolar concentration resulted in marked 
cardiovascular stimulation during anaesthesia. 
        Accordingly, a high minimum alveolar concentration of inhaled 
anaesthetic drugs is required to block the cardiovascular response to 
endotracheal intubation. This causes profound cardiovascular depression 
before endotracheal intubation. 
  
Pharmacology
of
Propofol
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PHARMCOLOGY OF PROPOFOL 
PROPOFOL 
Propofol is an intravenous sedative-hypnotic that was introduced 
for clinical use in 1977. It is famously called as “MILK OF AMNESIA” 
CHEMICAL STRUCTURE 
 
Propofol is a substituted isopropylphenol (2,6-diisopropylphenol) 
that is administered intravenously as 1 % solution in an aqueous solution 
of 10% soybean oil, 2.25% glycerol, and 1.2% purified egg phosphatide 
Administration of propofol, 1.5 to 2.5 mg/kg IV (equivalent to thiopental, 
4 to 5 mg/kg IV, or methohexital, 1.5 mg/kg IV) as a rapid IV injection  
produces unconsciousness within about 30 seconds. 
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PREPARATIONS 
 
DIPRIVAN (1%) 
Current formulations of propofol use a 10% soybean oil as the oil 
phase and 1.2% egg phosphatide as the emulsifying agent that is 
composed of long-chain triglycerides 2.25% glycerol. The generic 
formulation of propofol incorporates sodium metabisulfite (0.25 mg/mL) 
or 0.005% sodium edenate as the preservative and has a lower pH (4.5 to 
6.4). Propofol, unlike thiopental, etomidate and ketamine, is not a chiral 
compound. 
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AMPOFOL 
More recently a lower lipid formulation of propofol has been 
introduced into clinical practice.it contains 5%soyabean oil, 0.6% egg 
lecithin. 
The increased “free” fraction of propofol leads to increased pain 
when injected into small veins. Therefore it is important to add lidocaine 
to the Ampofol formulation to minimize the pain on injection. 
AQUAVAN (FOSPROPOFOL) 
A new water soluble pro drug of propofol. This prodrug is rapidly 
hydrolyzed by plasma alkaline phosphatases in the circulation to release 
free propofol. It has slower onset but a similar recovery profile but does 
not cause pain on injection. A transient burning sensation has been 
reported following IV injection.  
OTHERS 
Diprifusor TCI devices , Propofol lipura 
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MECHANISM OF ACTION
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It is a selective modulator of gamma amino butyric acid (GABAA) 
receptors
(23)
 and it does modulate other ligand-gated ion channels at 
clinically used concentrations. Propofol exerts its sedative-hypnotic 
effects through a GABAA receptor interaction. GABA is the principal 
inhibitory neurotransmitter in the CNS. On activation of GABAA 
receptors, transmembrane chloride conductance increases, There is 
hyperpolarization of the postsynaptic cell membrane and this leads to 
functional inhibition of the postsynaptic neuron. The interaction of 
propofol (also etomidate and barbiturates) with specific components of 
GABAA receptors decreases the rate of dissociation of GABA from the 
receptor, leading to increase in the duration of the GABA-activated 
opening of the chloride channel which results in hyperpolarization of cell 
membranes. In similarity to volatile anesthetics, spinal motor neuron 
excitability, as measured by H-reflexes, is not transformed by propofol, 
suggesting that immobility during propofol anaesthesia is not caused by 
drug-induced spinal cord depression. 
Widespread inhibition of NMDA (N-Methyl –D-aspartate) receptor 
through sodium channel gating. Acts on GABAA and glycine receptors 
and dorsal horn of spinal cord and inhibits the excitatory action. Increases 
the Dopamine concentration in nucleus accumbens which is responsible 
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for sense of wellbeing, drug abuse potential and pressure seeking 
behavior. 
Decreases serotonin levels in area postrema. This causes the 
antiemetic effect. 
Pharmacokinetics 
Elimination Half-Time (hrs)           -  0.5-1.5 
Volume of Distribution (liters/kg)  -  3.5-4.5 
Clearance (mL/kg/min)                   -  30-60 
Metabolism 
Propofol metabolism in humans is both hepatic and extra hepatic. 
Hepatic metabolism is rapid and extensive, resulting in inactive, water-
soluble sulfate and glucuronic acid metabolites. These metabolites are 
excreted by the kidneys. Propofol undergoes ring hydroxylation by the 
enzyme cytochrome P-450 to form 4-hydroxypropofol which is then 
glucuronidated or sulfated. 
Clinical use 
Propofol is the induction drug of choice for many forms of 
anaesthesia, especially when rapid and complete awakening is required. 
35 
For induction 
The induction dose of propofol in healthy adults is 1.5 to 2.5 mg/kg 
IV, with blood levels of 2 to 6 mg/mL which produces unconsciousness 
depending on related medications and the patient's age 
For intravenous sedation 
The conscious sedation dose of 25 to 100 mcg/kg/minute IV. At 
this dose it produces minimal analgesic and amnestic effects. 
For maintenance of anaesthesia 
The typical dose of propofol for maintenance of anaesthesia is 100 
to 300 mcg/kg/minute, often used in mixture with a short-acting opioid. 
Nonhypnotic Therapeutic applications : 
 For Anti-emetic effect. 
 For Anti-pruritic effect. 
 For Anti-convulsant activity. 
 For attenuation of bronchoconstriction. 
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Effects on other systems 
Central Nervous System 
  Propofol causes a decrease in cerebral metabolic rate, cerebral 
blood flow and intracranial pressure. The change in PaCo2 is similar to 
change in cerebral blood flow velocity. Propofol produces cortical 
electroencephalographic (EEG) changes that are similar to those of 
thiopental, At higher doses it produce burst suppression of cortical 
somatosensory evoked potentials which is used to monitoring spinal cord 
function. These functions are not significantly modified in the presence of 
propofol alone, but on addition of nitrous oxide or a volatile anesthetic 
results in decreased amplitude. 
Cardio vascular system 
          Propofol produces decreases in systemic blood pressure
(24)
 that are 
greater than thiopentone . The decrease in blood pressure is due to 
changes in cardiac output and systemic vascular resistance. Inhibition of 
sympathetic vasoconstrictor nerve activity by propofol causes relaxation 
of vascular smooth muscle. A negative inotropic effect of propofol, is due 
to secondary to inhibition of trans-sarcolemmal calcium influx which 
results in decrease of intracellular calcium availability for cardiac 
muscles to contract. Stimulation produced by direct laryngoscopy and 
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intubation of the trachea reverses the blood pressure effects of propofol. It 
is more effective than thiopental in blunting this presser response. 
Respiratory System 
       Apnea occurs in 25% to 35% of patients after induction of 
anaesthesia with propofol, this is due to dose dependent depression of 
ventilation. It also depresses the central chemoreceptors which is the 
reason for decreased response to hypercarbia. It causes bronchodilation 
and decrease the incidence of intraoperative wheezing in patients with 
asthma.  
Hepatic and Renal Function 
        Propofol has no effect hepatic or renal function as reflected by 
measurements of liver transaminase enzymes or creatinine 
concentrations. On prolonged infusions of propofol, there are cases 
associated with hepatocellular injury accompanied by lactic acidosis, 
rhabdomyolysis and arrhythmias.  
Coagulation: 
       Inhibits platelet aggregation, by proinflammation lipid mediators that 
includes thromboxane A2 and platelet-activating factor. 
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Side effects 
 Allergic reactions 
 Lactic acidosis 
 Pro convulsant activity 
 Abuse potential 
 Pain on injection. 
PROPOFOL INFUSION SYNDROME 
 
Propofol infusion syndrome (PRIS) is a rare syndrome that occurs 
in patients, who are on prolonged propofol infusion for sedation.it occurs 
when more than 4mg/kg/hr of propofol is infused for more than 24 hrs. It 
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is associated with cardiac failure, rhabdomyolysis, metabolic acidosis, 
and kidney failure, which are often fatal. High blood potassium, high 
blood triglycerides, and liver enlargement is due to direct mitochondrial 
respiratory chain inhibition or impaired mitochondrial fatty acid 
metabolism. It is common with children, and critically ill patients and 
those whose are receiving catecholamines and glucocorticoids. Early 
recognition of this syndrome is very important and discontinuation of the 
propofol infusion decreases morbidity and mortality. Treatment is 
supportive measures. 
  
Pharmacology
of
Etomidate
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PHARMOCOLOGYOF ETOMIDATE 
ETOMIDATE 
 
Etomidate, carboxylated imidazole-containing compound. The 
imidazole nucleus of the etomidate renders it water soluble at an acidic 
pH and lipid soluble at physiologic pH. 
COMMERCIAL PREPARATION 
 With propylene glycol 35% 
 Fat emulsion 
 Oral preparation for transmucosal delivery 
 Acidic pH 6.9 pKa 4.2, poorly water soluble 
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MECHANISM OF ACTION 
Etomidate
 (25)
 is a relatively selective as a modulator of GABA   
receptors. It exerts its effect by binding directly to a specific site or sites 
on the protein of GABAA receptors and enhancing the affinity of the 
inhibitory neurotransmitter. 
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PHARMACOKINETICS 
The volume of distribution (Vd) of etomidate is large, leading to 
considerably large tissue uptake. Etomidate reaches the brain rapidly, 
reaching peak levels within 1 minute after IV injection. The redistribution 
of the drug from brain to inactive tissue sites leads to rapid awakening 
following single dose of etomidate. Rapid metabolism is also adds to its 
prompt recovery 
METABOLISM 
  Hydrolysis of the ethyl ester side chain to its carboxylic acid ester, 
results in a water-soluble and pharmacologically inactive compound. 
Hydrolysis is nearly complete, < 3% of an administered dose of etomidate  
excreted as unchanged drug in urine. The clearance of etomidate is about 
five times of thiopental; this reflect  shorter elimination half-time of 2 to 
5 hours. 
CLINICAL USES 
Etomidate can be used as an alternative to propofol or barbiturates 
for the IV induction of anaesthesia, especially when there is unstable 
cardiovascular system. Standard induction dose of etomidate is 0.2 to 0.4 
mg/kg. The onset of unconsciousness occurs within one arm-to-brain 
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circulation time.  Involuntary myoclonic movements are common during 
the induction. 
The limiting for clinical use of etomidate following induction of 
anaesthesia is the ability of this drug to transiently depress adrenocortical 
function. 
SIDE EFFECTS 
Central Nervous System 
         Potent direct cerebral vasoconstrictor that decreases cerebral blood 
flow and CMR02, 35% to 45%, etomidate produces a pattern on the EEG 
that is similar to thiopental.  The frequency of excitatory spikes on the 
EEG is greater with etomidate than with thiopental and methohexital, 
must be cautiously used in patients with seizure disorder. 
Cardio Vascular System 
         At 0.3 mg/kg IV of etomidate there are minimal changes in heart 
rate, stroke volume, or cardiac output. The mean arterial blood pressure 
may decrease up to 15% due to decreases in systemic vascular resistance. 
The decrease in systemic blood pressure is similar to changes in systemic 
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vascular resistance. This suggests that administration of etomidate to 
acutely hypotensive patients could result in sudden hypotension. 
        At induction dose of etomidate 0.45 mg/kg there is decrease in 
systemic blood pressure and cardiac output. The cardiovascular effects of 
etomidate and thiopental are comparable when given continuously to 
patients with severe valvular heart disease. 
VENTILATION 
         The depressive effects of etomidate on ventilation seems to be less 
significant than barbiturates, although apnea may occasionally occur on a 
rapid IV injection of the drug. 
PAIN DURING INJECTION 
         With the use of lipid emulsion vehicle, Pain on injection and 
venous irritation has been virtually eliminated. 
MYOCLONUS 
        The mechanism of etomidate-induced myoclonus is due to 
disinhibition of subcortical structures which suppress extrapyramidal 
motor activity. In many patients with excitatory movements, EEG shows 
early slow phase which corresponds to the beginning of deep anaesthesia. 
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ADRENO CORTICAL SUPPRESSION
(26) 
 
          Inhibition of the conversion of cholesterol to cortisol by etomidate 
causes adrenocortical suppression. The mechanism of which is due to 
dose-dependent inhibition of the conversion of cholesterol to cortisol. The 
particular enzyme inhibited by etomidate appears to be 11-beta-
hydroxylase as shown by the accumulation of II-deoxycorticosterone. 
This enzyme inhibition lasts 4 to 8 hours after an induction dose of 
etomidate. 
 
ALLERGIC REACTIONS 
       The incidence of allergic reactions following administration of 
etomidate is very low with low flows for prolonged periods. 
Materials
and
Methods
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MATERIALS AND METHODS 
STUDY CENTRE  
ESIC MEDICAL COLLEGE AND PGIMSR, KK NAGAR,   
CHENNAI- 78. 
After institutional ethical committee approval, study was conducted 
in sixty patients between 20-50 years of age, of either sex, weighing 40 to 
80 kg and ASA grade I or II scheduled for elective surgery under general 
anaesthesia after obtaining informed consent from the patients. 
DURATION OF THE STUDY 
Jan 2017 – May 2018 
STUDY DESIGN  
Randomized double blinded controlled interventional study 
METHODS  
After institutional ethical committee approval, study was conducted 
in sixty patients between 20-50 years of age, of either sex, weighing 40 to 
80 kg and ASA grade I or II scheduled for elective surgery under general 
anaesthesia after obtaining informed consent from the patients. 
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SAMPLE SIZE 
        Based on a previous study by Masoudifar et al, it was seen that 
patients who received propofol (26%) had hypotension  following 
intubation compared to etomidate (8%). Based on this study, the sample 
size was calculated using n Master 2.0 software with an alpha error of 5% 
and power of 80%. Sample size was found to be 25 per group and 
rounded off to 30 per group to account for drop outs.  
ANALYSIS PLAN  
Collected data were analysed using statistical package SPSS 
version 21.0 
INCLUSION CRITERIA 
 20 – 50 years of either sex 
 Weight 40 to 80 kgs. 
 ASA grade I and II. 
 Mallampati grade I and II. 
EXCLUSION CRITERIA 
 Patient refusal. 
 Emergency surgeries. 
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 Patients with cardiovascular diseases like Ischemic heart 
disease(IHD) and hypertension. 
 Existence of considerable pathology in pharynx/larynx. 
 Patients on beta blockers and antihypertensive medication. 
 Diabetic  patients. 
 Known history of allergy to propofol or etomidate.  
 History of seizure disorder 
PREOPERATIVE PREPARATION 
        All the patients were subjected to basic haematological and 
biochemical investigations which included hemoglobin, total count, 
differential count, platelet count, renal and liver function tests, random 
blood sugar. 12 lead ECG, chest x ray and USG abdomen were also taken 
for all the patients. 
       The patients were kept nil per oral for 8 hours before surgery. All the 
patients were given tablet Alprazolam 0.25 mg, tab Ranitidine 150 mg 
and tab Metoclopramide 10 mg on the night before the surgery. Tab 
ranitidine 150 mg and tab metoclopramide 10 mg on the morning of 
surgery given at 6 am with sips of water  
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       On arrival to the preoperative room, informed consent was 
obtained for the participation of the patient in the study. The patients 
were randomly allocated into two groups by sealed envelope  technique 
into: 
GROUP A–Propofol 30 patients 
GROUP B- Etomidate 30 patients 
Patient was shifted to the operation theatre by trained personnel on 
a trolley. 
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PROCEDURE DETAILS 
 WHO CHECKLIST was performed for all the patients. 
 In operation theatre, standard monitors - Pulse oximetry for 
saturation (SpO2), Noninvasive blood pressure monitoring (NIBP), 
Electrocardiogram (ECG), ETCO2 were connected and baseline 
pulse rate, mean arterial pressure, ETCO2 and oxygen saturation 
were recorded. Intravenous line access obtained with 18 G cannula 
and crystalloid infusion started. Airway cart and rescue measures 
were kept ready. 
 Premedication: Injection midazolam 0.025mg/kg IV, injection 
glycopyrrolate 0.05mcg/kg  IV and injection fentanyl 2µg/kg IV. 
Hemodynamic variables were noted 
 Preoxygenation was done with 100% oxygen for 5 minutes 
 For Induction Group A patients received Inj Propofol 2.5 mg/kg IV   
 For Induction Group B patients received Inj Etomidate 0.3mg/kg 
IV 
 All the drugs that were used in the study were prepared by myself. 
It was decided that if any complication or untoward incidence 
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arise, blinding will be unfolded, patients will be treated 
accordingly. Drug given by anaesthesiologist who were blinded 
during the study. Speed of injection (10 secs) were equal in both 
the groups. After induction of anaesthesia, hemodynamic variables 
were recorded. 
        After loss of consciousness, which was confirmed by inability to 
respond to verbal commands and loss of eyelash reflex, Inj. vecuronium 
(0.08 mg/kg) was given; patient was ventilated with oxygen: nitrous 
oxide @ 33% : 66% and Isoflurane 1% dial concentration. Laryngoscopy 
and endotracheal intubation was done by experienced anesthesiologist 
who is  blinded after 5 minutes. Duration of laryngoscopy was kept less 
than 10 seconds. Cases were excluded when laryngoscopy time more than 
10 seconds or in patient with unanticipated difficult airway and was 
proceeded according to difficult airway algorithm. Trachea was intubated 
with adequate size endotracheal tube. Proper placement of endotracheal 
tube was confirmed by capnography and 5 point auscultation of chest. 
Following successful placement of ET tube anaesthesia was maintained 
with isoflurane 1-1.5% dial concentration and oxygen-nitrous oxide at the 
ratio of 33%:66%. Vitals were recorded at induction, post induction, 1, 2, 
3,5 and 10 minutes after intubation. Later, the  anaesthesia was 
maintained with standard protocol. 
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PATIENT FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASSESSMENT CLINIC 
Assessed with Investigations 
ASA I and ASA II of either Sex  20-50 Years 
40 – 80 Kgs     Informed Consent 
ON THE DAY OF SURGERY 
Randomization (Sealed Envelope Technique) 
GROUP A GROUP B 
Patients were shifted to the operation theatre by a trained personnel in a trolley 
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Vitals measurement at specified intervals in both groups as  
mentioned in the proforma,. 
 
  
Inside Theatre 
Monitors were connected 
Intravenous line access 
Baseline vitals measurement 
 
Airway cart and rescue measures 
WHO CHECKLIST 
GROUP A 
PRE MEDICATION IN BOTH GROUPS 
 
Tab. Ranitidine 150mg, Tab, Metoclopromide 10 mg @ 6 am 
Inj. glycopyrrolate 0.05 mcg/kg + Inj. midazolam 0.025 mg/kg + Inj. 
fentanyl 2 mcg/kg half an hour before procedure  
 
 
INDUCTION 
Inj. propofol 2.5 mg/kg 
INDUCTION 
Inj. etomidate  0.3 mg/kg 
GROUP B 
Observation
and
Results
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OBSERVATION AND RESULTS 
        The data collected was analyzed using SPSS software version 21 
(statistical package for social science). Continuous variables were given 
by means with standard deviation. Categorical variables were given by 
frequency and percentages. Student t-test was used for testing the 
significance of all the variables, means and standard deviation. Chi – 
square test was used to compare the proportions. All the statistical results 
were considered significant at the p value of less than 0.05. 
 
 
 
Total number of 
eligible 
patients=76 
No. of patients 
who gave 
consent = 60 
Randomization 
to propofol 
group=30 
Randomization 
to Etomidate 
group= 30 
Analysis done on 60 patients 
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CHART-1 
GENDER DISTRIBUTION 
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TABLE-1 
GENDER DISTRIBUTION 
 
PROPOFOL ETOMIDATE TOTAL 
NO % NO % NO % 
MALE 15 50.00 16 53.33 31 51.67 
FEMALE 15 50.00 14 46.67 29 48.33 
TOTAL 30 100 30 100 60 100 
SEX RATIO 
(Male: Female) 
15 : 15 16 : 14 31 : 29 
Chi square 
value 
0.07 
df 58 
p-value 0.80* (Not  Significant) 
 
*P value >0.05 Not Significant 
       Propofol and Etomidate groups were comparable with respect to 
gender distribution. Male and female were more or less equally 
distributed in both the groups. There were 15 males and 15 females in the 
propofol group and 16 males and 14 females in the etomidate group. The 
P value was 0.08 therefore statistically not significant. 
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CHART-2 
AGE DISTRIBUTION 
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TABLE- 2 
AGE DISTRIBUTION 
Age 
PROPOFOL ETOMIDATE 
NUMBER % NUMBER % 
20 – 30 17 56.67 9 30 
30 – 40 7 23.33 9 30 
40 – 50 6 20 12 40 
TOTAL 30 100 30 100 
Mean ± SD 32.03 ± 14.07 33.07± 10.01 
t-value 0.33 
Df 58 
p-value 0.074* (Not  Significant) 
 
*P value >0.05 Not Significant 
Patient in the age group of 20 to 50 years were included in the 
study. Propofol group had a mean age of 32.03 ±14.07 years and 
Etomidate group with the mean age of 33.07± 10.01 years. The mean age 
was comparable in both the groups with a P value of 0.074. 
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CHART-3 
WEIGHT 
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TABLE-3 
WEIGHT 
PROPOFOL ETOMIDATE 
t-value Df p-value 
MEAN SD MEAN SD 
60.03 6.52 61.67 6.98 0.94 58 0.06* 
               
*P value >0.05 Not Significant 
With respect to weight both the groups were comparable with each 
other. 
Mean weight of propofol group is 60.03±6.25 and etomidate 
61.67± 6.98 the p value is 0.06 which is statistically not significant. 
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CHART-4 
ASA GRADE 
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TABLE-4 
ASA GRADE 
 
ASA GRADE 
PROPOFOL ETOMIDATE 
NO. % NO. % 
1 12 70.00 11 36.67 
2 18 30.00 19 63.33 
TOTAL 30 100 30 100 
Chi square 
value 
0.70 
Df 58 
p-value 0.79* (Not  Significant) 
 
*P value >0.05 Not Significant 
American society of Anaesthesiologist physical status were 
comparable in both the groups with the p value of 0.79.  Thus statistically 
not significant. 
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CHART 5 
HEART RATE 
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TABLE-5 
HEART RATE 
 Variables 
PROPOFOL ETOMIDATE 
t-
value 
Df 
p-
value MEAN 
HR 
SD MEAN SD 
PRE OP 76.50 10.04 80.33 9.42 1.53 58 0.13* 
PRE 
MEDICATION 
73.37 9.35 78.27 9.29 2.04 58 0.05 
INDUCTION 79.47 11.62 79.23 9.64 0.09 58 0.93* 
INTUBATION 85.83 20.14 86.07 8.71 0.06 58 0.95* 
1 MIN 91.43 13.17 85.33 7.93 2.17 58 0.03 
2 MIN 90.20 12.73 82.40 9.48 2.69 58 0.01 
3 MIN 89.67 9.46 82.40 9.92 2.91 58 0.01 
5 MIN 88.07 9.47 82.23 10.40 2.27 58 0.03 
10 MIN 85.27 11.84 80.70 8.95 1.69 58 0.10* 
 
. p value < 0.05: Significant             * p value > 0.05 : Not Significant 
   Heart rate in both propofol and etomidate group increased after 
intubation compared to the values at induction. In the propofol group, the 
heart rate increased by seven to twelve beats per minute. In the etomidate 
group the heart rate increased by three to seven beats per minute, which 
was measured during intubation and 1, 2, 3, and 5 mins after intubation. 
The difference was statistically significant. 
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CHART-6 
SYSTOLIC BLOOD PRESSURE 
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TABLE-6 
SYSTOLIC BLOOD PRESSURE 
Variables 
PROPOFOL ETOMIDATE 
t-
value 
Df 
p-
value MEAN 
SBP 
SD 
MEAN 
SBP 
SD 
PRE OP 126.20 9.07 128.40 7.67 1.01 58 0.32* 
PRE 
MEDICATION 
121.13 9.93 123.43 7.31 1.02 58 0.31* 
INDUCTION 111.17 9.05 122.27 6.36 5.50 58 0.001 
INTUBUTION 114.77 12.09 128.07 7.75 5.07 58 0.001 
1 MIN 107.57 18.03 123.20 7.36 4.40 58 0.001 
2 MIN 97.03 8.34 119.03 8.60 10.04 58 0.001 
3 MIN 95.43 6.71 116.20 6.66 12.03 58 0.001 
5 MIN 94.57 5.35 116.37 7.37 13.10 58 0.001 
10 MIN 97.70 7.95 116.60 7.18 9.66 58 0.001 
 
. p value < 0.05 : Significant    * p value > 0.05 : Not Significant 
       When compared with systolic blood pressure values at the induction, 
there was a greater change in the propofol group at intubation as well as 
1, 2, 3, 5 and 10 mins after intubation. The difference was statistically 
significant with respect to the etomidate group during the same period 
with a p value of < 0.05. 
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CHART 7 
DIASTOLIC BLOOD PRESSURE 
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TABLE-7 
DIASTOLIC BLOOD PRESSURE 
 
Variables 
PROPOFOL ETOMIDATE 
t-
value 
Df 
p-
value MEAN 
DBP 
SD 
MEAN 
DBP 
SD 
PRE OP 75.30 10.38 80.23 10.27 1.85 58 0.07* 
PRE 
MEDICATION 
72.80 9.83 77.10 8.86 1.78 58 0.08* 
INDUCTION 67.03 7.65 74.33 8.52 3.46 58 0.001 
INTUBATION 65.57 15.27 79.87 10.87 4.18 58 0.001 
1 MIN 63.17 7.00 75.93 9.66 5.86 58 0.001 
2 MIN 60.30 5.60 73.87 8.46 7.32 58 0.001 
3 MIN 58.53 5.26 71.90 7.10 8.28 58 0.001 
5 MIN 60.10 6.31 71.83 6.37 7.17 58 0.001 
10 MIN 62.10 4.91 71.17 5.94 6.45 58 0.001 
 
. p value < 0.05: Significant    * p value > 0.0 5: Not Significant. 
Following intubation the change in diastolic blood pressure was 
more in propofol group compared to etomidate group with respect to the 
values at induction. The difference between the two groups was 
statistically significant with the p value of < 0.05. 
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CHART-8 
MEAN ARTERIAL BLOOD PRESSURE 
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TABLE-8 
MEAN ARTERIAL BLOOD PRESSURE 
Variables 
PROPOFOL ETOMIDATE 
t-
value 
Df 
p-
value MEAN 
MAP 
SD 
MEAN 
MAP 
SD 
PRE OP 92.20 9.41 96.30 8.60 1.76 58 0.08* 
PRE 
MEDICATION 
88.87 9.02 93.07 7.30 1.98 58 0.05 
INDUCTION 80.20 11.28 90.60 7.21 4.26 58 0.001 
INTUBUTION 82.03 12.01 95.97 8.74 5.14 58 0.001 
1 MIN 78.33 8.10 91.63 7.94 6.42 58 0.001 
2 MIN 72.50 5.31 88.90 7.09 10.14 58 0.001 
3 MIN 70.87 4.81 86.70 5.37 12.04 58 0.001 
5 MIN 71.57 5.39 86.67 6.09 10.18 58 0.001 
10 MIN 73.93 4.76 86.37 5.14 9.72 58 0.001 
 
. p value < 0.05 : Significant     * p value >  0.05 : Not Significant 
          Mean arterial pressure is diastolic blood pressure + 1/3 of systolic 
blood pressure. The trend in Mean Arterial Pressure was similar to the 
trend in diastolic blood pressure. After intubation and 1, 2, 3, 5 and  
10 mins afterwards the mean arterial pressure values were compared in 
etomidate as well as propofol groups. The mean arterial pressure 
decreased by maximum of 9 mm of Hg in propofol group, whereas the 
mean arterial pressure deceased by maximum of 4 mm of Hg in etomidate 
group. The difference between the two groups was statistically significant 
with p value of < 0.05.  
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DISCUSSION 
          Rapid induction and hemodynamic stability with minimal side 
effects are the most important characteristics desired from an ideal 
induction agent. 
In this study we compared the hemodynamic response to 
endotracheal intubation using etomidate and propofol as induction agents 
in 60 patients with 30 patients in each group, within the age group of 20-
50 years of either sex, weighing 40-80 Kg. 
Regarding the underlying variables such as gender, age, weight and 
ASA physical status of the patients, there was no significant difference, 
thus the compounding effects of these variables had been neutralized. 
Regarding the weight, the propofol group had a mean of 60.03, and 
etomidate group had a mean of 61.03 but this difference between the 
groups, was not statistically significant.  
The baseline and premedication values of systolic blood pressure, 
diastolic blood pressure, mean arterial pressure, were comparable in both 
the groups (table 6, table 7, table 8). Following intubation with propofol, 
there were significant changes in systolic blood pressure, diastolic blood 
pressure and mean arterial pressure compared to etomidate group and p 
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values at various time intervals remained significant (<0.05). This 
hypotension with propofol due to decrease in preload, was managed with 
fluids, and by decreasing concentration of inhalation agent.  
Hug et al
(33)
 conducted a study in 25,000 patients, he found out that 
propofol caused bradycardia in 4.2% patients and hypotension in 15.7% 
patients. In our study there was no incidence of bradycardia but 
significant hypotension occurred in 6 patients out of 30 patients which is 
around 20% which is comparable with the above study.  
      The effect of etomidate and propofol on heart rate is controversial. 
According to studies of Siedy J et al
(27)
 , Ghafor et al
(28)
 and Kaur et al
(29)
 , 
Mean heart rate was comparable in both the groups. Heart reate may 
increase or decrease, or these changes can be minimal following 
induction with these agents. The reason for this difference is not clear.  
In the studies of Ulsamer et al
(30)
, Moffat et al
(31)
 they found that 
Etomidate was associated with unacceptably sudden increase in heart 
rate, while Shah et al
(9)
 reported sustained increase in heart rate with 
Propofol. In our study, the change in heart rate was not much significant 
at induction and intubation in both the groups but etomidate was found to 
maintain heart rate within range of 3-7 beats per minute at 1,2,3,5 mins 
following intubation (table:5).  
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In the study of Kahlon A et al
(12)
, they found that etomidate caused 
myoclonus around 76% in placebo group, 44% in lignocaine group and 
28% in midazolam group . In our study myoclonus was observed in 4 out 
of 30 patients (13.33%) who were induced with etomidate, while no 
equivalent signs were noted in propofol group. This finding correlates 
with the above study. 
  Picard P et al
(32)
 did a study on 6264 patients which showed that on 
an average, 70% of patients complained,  pain on injection. In our study, 
22 patients out of 30 patients complained of pain on injection(73.33%). 
Shah et al
(9)
,
 
Masoudifar
(13)
 and Beheshtian, Aggarwal
(7)
  et al, 
MeenaKumari
(6)
, all the above studies showed that the changes in systolic 
blood pressure, diastolic blood pressure and mean arterial pressure were 
less in etomidate group compared to propofol group which is in total 
agreement with our study (table 6,7 &8 ). 
There was no incidence of nausea and vomiting in both the groups. 
No other complications were noted in both etomidate and propofol group.   
  
Limitation
of the Study
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LIMITATION OF STUDY 
The study design had some limitation. We did not measure plasma 
cortisol and adrenocorticotrophic hormone level due to nonavailability of 
the above tests in our institution.  
 
 
 
 
 
 
 
 
  
Summary
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SUMMARY 
        The aim of the study is to compare etomidate and propofol 
induction on hemodynamic response to laryngoscopy and intubation. The 
study was conducted in 60 ASA I & II patients in the age group of 20 to 
50 years who were posted for elective cases under general anaesthesia. 
Their baseline heart rate, systolic blood pressure, diastolic blood pressure, 
SpO2 and ETCO2 were noted. Both the groups were premedicated with 
iv glycopyrrolate 0.05mcg/kg, iv midazolam 0.025mg/Kg, iv fentanyl 
2mcg/Kg. Following premedication the above variables were again noted. 
Group A patients were induced with iv propofol at the dose of 2.5mg/Kg 
and Group B patients received iv etomidate at 0.3mg/Kg.  In both the 
groups, Injection vecuronium was given at the dose 0.08mg/Kg and they 
were maintained with O2:N2O =33%:66% and Isoflurane 1% dial 
concentration. Laryngoscopy was performed by trained anesthesiologists 
after 5 mins. Duration of laryngoscopy was kept at a maximum of 10 
seconds. Trachea was intubated with appropriate size endotracheal tube. 
The variables (HR, SBP, DBP, MAP, SpO2) were measured during 
induction, intubation and post intubation at intervals of 1,2,3,5 and 10 
mins. 
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On comparing the two groups, the following results were obtained – 
1) Age, Sex, Weight and ASA status were comparable in both the 
groups. 
2) Propofol was found to produce hypotension in more or less 20%-
30% of patients irrespective of the underlying condition. 
3) Etomidate was found to maintain hemodynamic stability though 
there were no significant difference in heart rate variability in both 
the groups during laryngoscopy and intubation.  
4) Myoclonus was seen in 4 out of 30 patients induced with 
Etomidate, pain on injection was more common with Propofol.  
 
 
 
  
Conclusion
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CONCLUSION 
As per the results of the study, Propofol produced more 
hemodynamic changes than Etomidate. Thus we conclude that Etomidate 
is more stable in terms of hemodynamic stability.  
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PATIENT CONSENT FORM 
Study title  
‘Comparison of Propofol and Etomidate induction on haemo 
dynamic response to endotracheal intubation’ 
Study centre 
ESIC Medical College & PGIMSR, K. K. Nagar, Chennai -78 
Participant’s Name: 
Age: Sex: 
Diagnosis: 
Plan: 
I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask the question and all my 
questions and doubts have been answered to my satisfaction. 
I have been explained about the pitfall in the procedure. I have 
been explained about the safety, advantage and disadvantage of the 
technique. I understand that my participation in the study is voluntary and 
that I am free to withdraw at any time without giving any reason. 
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I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both 
in respect to current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study. I understand that my 
identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use 
of any data or results that arise from the study. 
I have been explained that the anaesthetic technique is a standard 
and approved technique. This may help in future research in the field of 
anaesthesia. I consent to undergo this procedure. 
 
Insurance No:                             Signature / thumb impression of patient 
Date :  
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J¨¦uÀ £iÁ® 
1. GÚUS AÖøÁ ]Qaø\ø¯ ö\´²©õÖ ©¸zxÁº ©ØÖ® 
SÊÂÚøµ ÷ÁsiU öPõÒQ÷Óß. 
2. ÷{õ°ß ußø© : 
 ]Qaø\ ¬øÓ : 
 CøÁ AøÚzx® GÚUS ©¸zxÁº -»® öuÎÁõP ÂÍUP¨ 
£mhÚ. 
3. GÚUS ¬Ê ©¯UPzvß÷£õx ¦÷µõ¨÷£õ£À ©ØÖ® C÷hõª÷hm  
(Propofol & Etomidate) GßÓ ©¯UP ©¸¢x öPõkzx AÖøÁ 
]Qaø\ ©ØÖ® B´Ä ö\´xöPõÒÍ \®©vUQ÷Óß. 
4. CÁØÔß ¤ß ÂøÍÄPøÍ ©¸zxÁº -»® AÔ¢x öPõs÷hß. 
5. AøÚzx ©¸zxÁ ]Qaø\ ¬øÓPÎß |øÓPÐ® SøÓPÐ® 
GÚUS ÂÍUP¨£mhÚ. 
6. ÷©÷» öPõkUP¨£mkÒÍ AøÚzx® ©¸zxÁ©øÚ {ßöÚÔ 
(Ethics) SÊÂß Áøµ¬øÓUS Em£m÷h {hUS® GÚ ©¸zxÁº 
ÂÍUQÚõº. ÷©¾® C¢u ]Qaø\ ¬øÓPÐUS Ehß£h ©ÖUPÄ® 
GÚUS E¶ø© Esk Gß£øu AÔ÷Áß. 
7. Gß ]Qaø\°ß÷£õx QøhUS® uPÁÀPøÍ ©¸zxÁ 
Bµõ´a]US £¯ß£kzuÄ® AÎUQ÷Óß. 
{õß C¢u J¨¦uÀ £iÁzøu £izu ¤ßÚ÷µ / £izx Põs¤UP¨£mh 
¤ßÚ÷µ, Cuß \õµõ®\zøu ¬ÊÁx¬õP ¦¶¢xöPõsh ¤ß÷Ú 
¬Ê©Úxhß \®©vzx øPö¯ÊzvkQß÷Óß. 
\õm]        J¨¦uÀ AÎ¨£Áº 
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PROFORMA 
Name of the patient: 
Age: 
Sex: 
Weight: 
Height: 
Insurance No: 
Group: 
Date: 
Procedure: 
Anaesthetic plan: 
PRE OPERATIVE DETAILS 
ASA GRADING 
MALLAMPATTI GRADING 
REMARKS 
 
 
PRE OPERATIVE 
HR:  SBP:  DBP:  MAP:  SPO2 
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INTRAOPERATIVE 
DRUGS: 
Vitals 
Pre 
Op 
Pre 
Med 
Induction Intubation 
1 
Min 
2 
Min 
3 
Min 
5 
Min 
10 
Min 
HR          
SBP          
DBP          
MAP          
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1 E MALATHY 35 F 62 ACUTE	CHOLECYSTITIS LAP	CHOLECYSTECTOMY 2 77 80 83 89 89 88 84 92 88 130 125 120 121 124 118 114 127 124 101 87 82 86 87 84 84 85 80 111 100 95 98 99 95 94 99 95 100 100 99 100 99 98 100 98 1002 P MANIKANDAN 29 M 78 RT	GYNECOMASTIA WEBSTER'S	PROCEDURE 2 62 58 83 102 90 94 95 92 90 138 111 132 117 109 105 101 100 97 96 72 81 78 81 71 66 65 64 110 85 98 91 90 82 78 77 75 98 99 100 98 100 99 98 100 993 E JAYAPAUL 40 M 78 RT	RENAL	CALCULI RT	PCNL 2 84 81 83 91 81 74 73 66 68 136 134 132 131 144 111 116 107 102 98 96 99 94 91 81 81 68 67 111 109 110 106 109 91 93 81 79 98 100 100 98 100 100 98 99 1004 P SAJEDHA 32 F 60 CAUDA	EQUINA	SYNDROME DISCECTOMY 2 93 92 111 116 127 133 104 99 116 124 115 105 108 106 85 96 107 115 84 90 73 85 66 65 65 77 77 97 98 84 93 79 72 75 87 90 98 100 98 98 98 100 98 100 1005 E KRIHNA	MOORTHY 36 M 57 LT	RENAL	CALCULUS	 LT	PCNL 1 56 60 58 70 73 52 56 55 60 130 117 116 130 120 112 108 105 109 90 91 85 93 91 92 87 77 80 103 100 95 105 101 99 94 86 90 99 99 98 99 98 98 99 100 996 E SATISH 25 M 55 RT	RENAL	CALCULI RT	PCNL 1 93 92 96 102 98 91 87 77 74 122 120 116 126 127 118 119 113 108 90 85 69 99 96 75 75 72 67 101 97 85 108 106 89 90 86 81 99 99 98 99 98 98 99 99 997 P ASHWINI 26 F 54 HEMANGIOMA	SCALP EXCISION 1 68 76 90 80 105 103 106 95 80 140 142 121 104 102 86 84 96 95 90 93 68 51 50 61 51 65 63 107 109 86 69 67 69 62 75 74 100 98 99 100 99 98 100 99 988 E THIYAGARAJAN 50 M 60 RT	CSOM RT	CORTICAL	MASTOIDECTOMY 2 84 88 86 96 88 89 93 92 89 123 108 118 116 113 110 106 104 110 74 79 73 81 71 66 65 64 68 90 89 88 93 85 81 79 77 82 100 98 99 100 99 99 100 98 989 P SOMAIAH 22 M 60 RT	CSOM ST	CORTICAL	MASTOIDECTOMY 1 82 84 79 118 118 75 71 76 72 130 133 103 107 102 107 102 100 95 88 88 59 65 62 65 62 57 57 102 103 74 79 75 79 75 71 70 99 98 100 99 100 99 99 98 9810 E SHANMUGHAM 33 M 65 FUNGAL	SINUSITIS FESS 2 68 72 69 81 71 69 63 90 83 130 123 123 153 136 144 115 114 100 90 83 84 104 90 90 83 81 72 103 96 97 120 105 108 94 92 81 99 99 100 99 100 100 99 98 9911 P SUGANYA 30 F 63 PRIMARY	INFERTILITY DIAGNOSTIC	LAPROSCOPY 1 71 68 69 88 86 84 81 81 80 134 128 100 98 88 92 96 97 110 90 83 80 78 68 71 68 72 70 105 98 87 85 75 78 77 80 83 98 99 99 98 99 100 98 99 9912 E SHANKARI 47 F 62 MULTI	NODULAR	GOITRE	 TOTAL	THYROIDECTOMY 2 81 78 78 88 83 81 80 78 76 146 138 134 140 130 127 119 122 118 88 81 80 98 81 84 78 77 71 107 100 98 112 97 98 92 92 87 98 100 99 98 99 99 98 99 10013 E ILAKKIYAMATHI 26 F 65 #CLAVICLE	 ORIF 1 75 78 80 86 87 85 80 87 83 146 130 121 124 118 115 110 125 120 98 90 78 80 81 80 80 81 77 114 103 92 95 93 92 90 96 91 98 98 98 98 98 99 98 100 9814 E NEELAVATHI 28 F 57 RT	THYROID	NODULE RT	HEMI	THYROIDECTOMY 2 88 87 80 92 82 82 86 88 82 132 118 128 126 123 120 116 114 120 74 79 73 81 71 66 65 64 68 93 92 91 96 88 84 82 81 85 99 100 98 99 98 98 99 98 10015 P DAIVANAYAKI 38 F 55 PRIMARY	INFERTILITY DIAGNOSTIC	LAPROSCOPY 2 64 61 85 100 92 96 92 91 94 128 101 122 107 99 95 90 90 91 85 72 71 70 71 61 60 58 58 99 82 88 82 80 72 70 69 69 99 98 98 99 98 98 99 100 9816 P ILAVARASI 45 F 59 L4-L5	DISC	PROLAPSE											 L4-L5	DISCECTOMY 2 66 72 88 78 98 90 92 85 72 134 136 117 98 96 84 86 92 90 85 90 65 57 50 56 54 62 65 101 105 82 71 65 65 65 72 73 100 98 99 100 99 98 100 98 9817 E SATHAYANARAYANAN 49 M 72 #CLAVIVLE	LT ORIF 2 90 88 96 98 88 80 87 92 91 123 119 127 124 120 117 115 119 120 90 84 80 81 87 80 77 75 74 101 96 96 95 98 92 90 90 89 98 98 99 98 99 99 98 98 9818 P KANHU	CHARAN	 42 M 65 RT	PARASYMPHYSIS# ORIF 1 68 64 66 70 68 73 77 75 78 123 120 121 109 104 97 99 100 103 78 72 70 68 60 58 58 60 62 93 88 87 82 75 71 72 73 76 99 99 100 99 100 99 99 98 9919 E SOFIA	EZHILARASI 42 F 65 RT	LOBE	SOLITARY	NODULE	THYROID RT	HEMI	THYROIDECTOMY 2 71 73 72 77 81 76 78 75 74 123 118 126 121 128 124 121 124 126 80 78 77 81 76 74 72 71 70 94 91 93 94 93 91 88 89 89 100 99 98 100 98 100 100 99 9920 P NAVANEETH	KUMAR 28 M 70 RT	GYNECOMASTIA RT	WEBSTER'S	PROCEDURE 2 59 61 59 70 77 76 70 68 66 114 116 106 90 88 84 98 99 107 68 66 64 60 58 55 57 60 61 83 83 78 70 68 65 71 73 76 100 100 99 100 99 98 100 99 10021 P ARUL	PRAVEEN 26 M 52DSR	LT	INFERIOR	TURBINATE	HYPERTROPHY SEPTOPLASTY 2 72 70 77 78 92 94 93 91 88 127 125 119 120 107 100 96 98 101 64 66 62 60 58 55 51 50 57 85 86 81 80 74 70 66 66 72 98 100 100 98 100 99 98 100 10022 E RAJESH 27 M 72 RT	MAXILLARY	POLYP	,DSR FESS	WITH	SEPTOPLASTY 2 80 82 87 88 90 91 88 86 84 134 128 127 135 127 125 120 121 126 77 75 71 77 70 68 70 72 71 96 93 90 96 89 87 87 88 89 98 99 100 98 100 100 98 100 9923 P VAISHNAVI 26 F 57 CHRONIC	TONSILLITIS TONSILLECTOMY 1 71 70 65 73 74 77 82 88 80 119 110 109 117 105 100 96 90 101 64 64 60 58 55 52 55 56 60 82 79 76 78 72 68 69 67 74 99 99 98 99 98 100 99 99 9924 E SARATH	 46 M 64 LT	PUJ	OBSTRUCTION LT	PYELOPLASTY 1 88 89 85 92 91 88 86 84 81 140 136 134 144 137 139 132 128 130 90 88 85 90 82 78 77 80 84 107 104 101 108 100 98 95 96 99 99 98 100 99 100 98 99 99 9825 P GEETHA 37 F 57DYSPLASIA	OF	RT	LAT	BORDER	OF	TONGUE WLE 1 76 73 77 75 81 83 87 83 80 119 116 100 109 107 90 88 92 98 67 67 68 70 70 68 63 58 59 84 83 79 83 82 75 71 69 72 100 98 100 100 100 100 100 98 9826 P KANAN 20 M 59 RT	SUBMANDIBULAR	SIALONIDITIS SUBMANDIBULAR	SIALADENACTOMY 2 93 91 90 104 99 100 101 99 96 120 124 111 128 103 100 94 90 98 71 70 68 72 66 60 55 58 57 87 88 82 91 78 73 68 69 71 98 98 99 98 99 100 98 98 9827 P LOGESH 22 M 62 DNS SEPTOPLASTY 2 68 64 71 79 81 84 88 82 78 126 120 107 134 115 100 98 90 95 72 74 68 70 66 55 54 53 55 90 89 81 91 82 70 69 65 68 99 99 99 99 99 99 99 98 9928 P ASHA 27 F 50 DERMOID	CYST	FOREHEAD EXCISION 2 71 70 63 90 84 83 78 77 75 140 134 111 144 119 104 100 98 96 82 80 71 84 71 60 63 67 69 101 98 84 104 87 75 75 77 78 100 99 98 100 99 99 100 99 9929 P PRAKASH 29 M 53 DSL SEPTOPLASTY 1 83 80 79 101 98 90 93 96 91 134 130 123 137 119 104 100 102 110 74 70 68 77 60 58 55 60 64 94 90 86 97 80 73 70 74 79 100 100 98 100 100 98 100 99 10030 E LATHAMARY	 36 F 54 IMPACTED	TOOTH SURGICAL	EXTRACTION 2 84 86 80 90 92 91 93 91 88 128 124 120 133 130 128 120 124 121 75 71 70 77 72 71 68 69 67 93 89 87 96 91 90 85 87 85 98 98 98 98 98 98 98 100 9831 P SOKKAMMAL 24 M 58 LT	EAR	ATRESIA LT	REVISION		MEATOPLASTY 1 78 77 74 4 70 68 77 68 60 118 116 90 107 92 84 80 88 92 72 71 60 71 61 55 58 56 60 87 86 70 83 71 65 65 67 71 98 99 99 98 99 98 98 98 9932 E VEERARAGAVAN 33 M 60 LT	CSOM LT	CORTICAL	MASTOIDECTOMY 2 78 78 76 84 80 82 83 81 79 128 123 120 134 131 128 122 119 120 81 74 80 76 77 74 71 78 70 97 90 93 95 95 92 88 92 87 98 100 99 98 100 99 98 99 10033 E JOTHIRAMAN 37 M 67 RT	#CLAVICLE ORIF 2 71 73 71 79 83 79 80 78 77 123 120 118 128 117 124 120 119 119 71 70 68 74 70 68 68 70 71 88 87 85 92 86 87 85 86 87 99 100 100 99 100 99 99 100 10034 P BANUPRIYA 24 F 63 SNT	LT	LOBE TOTAL	THYROIDECTOMY 1 76 77 70 89 95 101 99 87 84 119 116 104 110 103 97 94 90 88 68 65 60 67 58 55 54 50 57 85 82 75 81 73 69 67 63 67 99 98 98 99 98 100 99 100 9835 P RAFI 25 M 62 B/L	WEBSTERS 2 68 64 62 70 76 82 87 89 74 117 112 100 114 191 90 88 86 90 66 66 60 64 58 55 58 60 62 83 81 73 81 102 67 68 69 71 100 99 100 100 99 99 100 98 9936 E RAJESHWARI 35 F 74 PLANNED	PARENTHOOD LAP	STERILIZATION 2 63 60 63 71 77 70 68 68 67 128 125 124 129 120 119 118 117 120 71 70 68 70 68 66 66 68 70 90 88 87 90 85 84 83 84 87 98 98 98 98 98 98 98 100 9837 P VELAMMAL 36 F 76 CHRONIC	TONSILLITIS TONSILLECTOMY 2 94 86 85 93 104 101 99 95 99 104 102 100 117 109 104 98 90 96 60 62 60 58 60 58 55 50 60 75 75 73 78 76 73 69 63 72 99 99 99 99 99 98 99 98 9938 E VINOD 27 M 56 LEFT	COLLOID	GOITRE LEFT	HEMITHYROIDECTOMY 1 82 74 74 82 83 85 80 77 74 117 115 114 121 118 109 106 110 116 77 72 69 77 74 77 71 70 68 90 86 84 92 89 88 83 83 84 99 100 99 99 100 99 99 99 10039 E LALITHA 33 F 60 DENTAL	CYST CYST	EXCISION 2 69 60 64 70 73 70 71 68 70 132 130 125 127 120 121 124 119 120 68 64 60 65 60 68 60 62 60 89 86 82 86 80 86 81 81 80 100 100 100 100 100 99 100 100 10040 E MANIVANNAN 35 M 64 LT	TORN	EAR	 LT	EAR	RECONSTRUCTION 2 78 74 71 79 82 80 79 78 77 117 114 110 120 117 110 108 114 115 60 58 55 64 60 62 65 66 60 79 77 73 83 79 78 79 82 78 100 98 98 100 98 100 100 100 9841 P SARALA 36 F 60 GRADE3	DIFFUSE	GOITRE	 TOTAL	THYROIDECTOMY 2 75 70 73 88 89 79 86 77 75 119 115 110 102 98 90 86 89 92 60 55 57 64 60 58 57 60 61 80 75 75 77 73 69 67 70 71 99 98 99 99 98 98 99 98 9842 E GEETHARANI 29 F 58 LT	CSOM LT	CARTILAGE	TYMPANOPLASTY 1 92 87 93 99 104 101 104 103 102 132 128 120 122 117 109 103 100 114 81 78 69 65 64 60 62 60 64 98 95 86 84 82 76 76 73 81 99 98 100 99 98 99 99 98 9843 E HEMANTH	KUMAR 21 M 60 AC	POLYP FESS 1 78 76 76 83 80 82 85 81 78 127 123 119 129 119 114 117 110 108 77 72 70 81 77 74 70 68 70 94 89 86 97 91 87 86 82 83 98 99 100 98 99 100 98 98 9944 P SHOBANA 32 F 71 DENTAL	CYST PERIAPICAL	SURGERY 2 96 90 98 105 101 103 99 107 100 140 134 115 123 119 110 104 100 116 80 83 74 80 70 68 66 60 61 100 100 88 94 86 82 79 73 79 98 99 98 98 99 100 98 99 9945 E LAKSHAMANAN 46 M 80LIPOMA	B/L	TEMPOROCCIPITAL	REGION LIPOMA	EXCISION 1 80 74 74 81 82 86 83 80 78 129 126 118 120 114 112 117 119 115 75 72 68 73 70 68 66 69 71 93 90 85 89 85 83 83 86 86 98 100 98 98 100 98 98 99 10046 P SRINIVASAN 28 M 67 CHRONIC	DACRYOCYSTITIS ENDO	DCR 1 89 82 94 99 103 100 99 101 104 125 121 114 117 103 104 98 96 107 88 80 71 77 70 68 60 62 58 100 94 85 90 81 80 73 73 74 99 100 98 99 100 98 99 100 10047 E NELAVENI 27 F 58 CHRONIC	SINUSITIS FESS 1 95 92 90 96 99 90 91 93 94 118 116 110 120 116 108 105 109 111 80 75 71 82 77 74 70 71 70 93 89 84 95 90 85 82 84 84 99 99 99 99 99 98 99 100 9948 E KOLLAPURI 41 M 56 RIGHT	COLLOID	GOITRE RIGHT	HEMITHYROIDECTOMY 1 88 80 87 91 90 93 89 91 86 132 133 128 127 121 119 123 117 120 88 84 80 85 79 80 78 77 82 103 100 96 99 93 93 93 90 95 100 99 99 100 99 99 100 99 9949 P SENTHIL	KUMAR	 48 M 78 LEFT	COLLOID	GOITRE LEFT	HEMITHYROIDECTOMY 2 70 62 77 83 80 81 89 88 86 125 120 110 121 105 100 94 90 88 71 68 60 69 61 58 57 60 61 89 85 77 86 76 72 69 70 70 100 98 100 100 98 99 100 99 9850 E SHAHEENA	MARY 48 F 58 AC	DISLOCATION ORIF 2 92 88 86 94 96 93 98 95 91 131 128 132 130 128 125 122 127 129 80 78 75 83 81 82 77 79 74 97 95 94 99 97 96 92 95 92 100 99 100 100 99 100 100 98 9951 P ABHIRAMI 43 F 64 CA	BREAST LT	MRM 2 79 70 84 88 90 86 83 91 89 138 130 120 124 116 114 109 100 99 90 86 90 80 74 72 70 71 68 106 101 100 95 88 86 83 81 78 98 99 99 98 99 100 98 99 9952 E UMA 44 F 59 CHRONIC	SINUSITIS FESS 2 78 66 78 80 83 79 81 80 79 130 127 125 131 126 120 121 119 111 70 71 76 70 66 68 69 72 75 90 90 92 90 86 85 86 88 87 98 100 99 98 100 99 98 99 10053 P MANI 23 M 64 DEVIATED	SEPTUM	RT	SIDED SEPTOPLASTY 1 76 68 77 83 89 87 90 94 96 114 110 111 110 90 86 88 90 99 60 62 68 60 61 58 55 58 58 78 78 82 77 71 67 66 69 72 98 100 98 98 100 99 98 100 10054 E SIVASAMI 46 M 70 RIGHT	COLLOID	GOITRE RIGHT	HEMITHYROIDECTOMY 2 74 70 78 80 79 78 73 71 74 130 127 1123 129 120 119 121 124 117 80 76 74 81 77 79 73 75 79 97 93 424 97 91 92 89 91 92 99 99 98 99 99 98 99 100 9955 P DEEPA 34 F 60 MULTINODULAR	GOITRE SUBTOTAL	THYROIDECTOMY 2 85 74 86 88 95 97 89 88 90 124 121 106 110 100 94 101 98 90 66 61 60 57 59 60 65 66 70 85 81 75 75 73 71 77 77 77 99 99 98 99 99 98 99 99 9956 P SURESH 29 M 58 FRACTURE	NASAL	BONE REDUCTION 2 76 73 80 83 87 90 89 91 86 137 131 120 126 117 106 100 96 94 75 70 68 60 604 58 50 53 66 96 90 85 82 442 74 67 67 75 100 98 99 100 98 98 100 99 9857 E SHANTHA 46 F 63 IVDP	L4-L5 DISCECTOMY 2 93 88 92 95 94 88 89 93 91 114 110 119 124 117 114 118 110 114 63 60 64 58 59 57 60 61 63 80 77 82 80 78 76 79 77 80 100 98 99 100 98 99 100 98 9858 P LOGANAYAKI 42 M 70 LT	CA	BREAST MODIFIED	RADICAL	MASTECTOMY 1 77 70 79 81 93 97 91 90 88 129 120 117 126 111 100 105 97 90 74 70 68 61 71 60 55 59 60 92 87 84 83 84 73 72 72 70 99 98 100 99 98 99 99 98 9859 P GANDHIMATHI 50 F 63 PAROTID	TUMOR SUPERFICIAL	PAROTIDECTOMY 2 89 84 93 99 101 99 103 98 91 127 125 111 109 104 99 94 86 88 71 68 60 66 60 55 59 60 63 90 87 77 80 75 70 71 69 71 98 99 100 98 99 100 98 98 9960 E MANIKANDAN 28 M 60 CHRONIC	TONSILLITIS TONSILECTOMY 1 80 74 71 78 81 79 84 77 83 121 1120 119 127 118 112 110 111 115 70 72 77 70 73 70 69 73 72 87 421 91 89 88 84 83 86 86 98 99 100 98 99 100 98 99 99
MASTER	CHART
W
EI
GH
T
SL
	N
O
GR
O
UP
N
AM
E
AG
E
SE
X
MEAN		ARTERIAL		PRESSURE	(mmHg) 	SPO2
D
IA
GN
O
SI
S
SU
RG
ER
Y
ASA
HEART	RATE	(	/min) SYSTOLIC	BLOOD		PRESSURE	(mmHg) DIASTOLIC	BLOOD		PRESSURE	(mmHg)
